复发性多发性骨髓瘤何时及如何治疗。

Q1 Medicine

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2021-03-01 DOI:10.1200/EDBK_320129

Nitya Nathwani, Luca Bertamini, Rahul Banerjee, Francesca Gay, Nina Shah, Amrita Krishnan

{"title":"复发性多发性骨髓瘤何时及如何治疗。","authors":"Nitya Nathwani, Luca Bertamini, Rahul Banerjee, Francesca Gay, Nina Shah, Amrita Krishnan","doi":"10.1200/EDBK_320129","DOIUrl":null,"url":null,"abstract":"The treatment landscape for relapsed multiple myeloma has expanded considerably in recent years, as numerous agents with new mechanisms of action have been introduced, increasing responses even in advanced disease and prolonging survival. The wealth of novel regimens comes with the challenges of balancing toxicities and aligning a regimen with the biology of the myeloma and the nature of the relapse in conjunction with patient treatment history and personal preference. Herein, we provide an overview of treatment options for both early and late relapsing disease as well as a discussion of the role of emerging immune-based therapies.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":" ","pages":"358-375"},"PeriodicalIF":0.0000,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"When and How to Treat Relapsed Multiple Myeloma.\",\"authors\":\"Nitya Nathwani, Luca Bertamini, Rahul Banerjee, Francesca Gay, Nina Shah, Amrita Krishnan\",\"doi\":\"10.1200/EDBK_320129\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The treatment landscape for relapsed multiple myeloma has expanded considerably in recent years, as numerous agents with new mechanisms of action have been introduced, increasing responses even in advanced disease and prolonging survival. The wealth of novel regimens comes with the challenges of balancing toxicities and aligning a regimen with the biology of the myeloma and the nature of the relapse in conjunction with patient treatment history and personal preference. Herein, we provide an overview of treatment options for both early and late relapsing disease as well as a discussion of the role of emerging immune-based therapies.\",\"PeriodicalId\":37969,\"journal\":{\"name\":\"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting\",\"volume\":\" \",\"pages\":\"358-375\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1200/EDBK_320129\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/EDBK_320129","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 4

摘要

近年来，随着许多具有新机制的药物被引入，复发性多发性骨髓瘤的治疗前景已经大大扩大，即使在晚期疾病中也增加了反应并延长了生存期。新治疗方案的丰富带来了平衡毒性的挑战，并将治疗方案与骨髓瘤的生物学特性和复发的性质结合患者的治疗史和个人偏好相结合。在此，我们概述了早期和晚期复发疾病的治疗方案，并讨论了新兴的基于免疫的治疗方法的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

When and How to Treat Relapsed Multiple Myeloma.

The treatment landscape for relapsed multiple myeloma has expanded considerably in recent years, as numerous agents with new mechanisms of action have been introduced, increasing responses even in advanced disease and prolonging survival. The wealth of novel regimens comes with the challenges of balancing toxicities and aligning a regimen with the biology of the myeloma and the nature of the relapse in conjunction with patient treatment history and personal preference. Herein, we provide an overview of treatment options for both early and late relapsing disease as well as a discussion of the role of emerging immune-based therapies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Medicine-Medicine (all)

自引率

0.00%

发文量

期刊介绍： The Ed Book is a National Library of Medicine–indexed collection of articles written by ASCO Annual Meeting faculty and invited leaders in oncology. Ed Book was launched in 1985 to highlight standards of care and inspire future therapeutic possibilities in oncology. Published annually, each volume highlights the most compelling research and developments across the multidisciplinary fields of oncology and serves as an enduring scholarly resource for all members of the cancer care team long after the Meeting concludes. These articles address issues in the following areas, among others: Immuno-oncology, Surgical, radiation, and medical oncology, Clinical informatics and quality of care, Global health, Survivorship.